104.52  0.2 (0.19%)		06-12 16:00
Open: 104.44 High: 104.525 Volume: 687,400		Pre. Close: 104.32 Low: 102.6481 Market Cap: 6,805(M)

Short term
Mid term
Targets	6-month :	122.08	1-year :	142.59
Resists	First :	104.52	Second :	122.08
Pivot price	100.5
Supports	First :	96.56	Second :	91.65
MAs	MA(5) :	101.81	MA(20) :	98.9
	MA(100) :	81.77	MA(250) :	70.02
MACD	MACD :	3.4	Signal :	3.4
%K %D	K(14,3) :	88.8	D(3) :	78.2
RSI	RSI(14): 67.1
52-week	High :	104.52	Low :	47.25

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LNTH ] has closed below upper band by 5.6%. Bollinger Bands are 13.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	104.68 - 105.1	105.1 - 105.54
Low:	101.61 - 102.05	102.05 - 102.5
Close:	103.8 - 104.56	104.56 - 105.35

Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.

Wed, 10 Jun 2026
Lantheus Holdings gains after report it's evaluating a sale after offer - MSN

Tue, 09 Jun 2026
LNTH: TruVu launches regionally in late 2024, expanding PYLARIFY access and driving market growth - TradingView

Tue, 09 Jun 2026
LNTH: TruVu and Neuraceq expansions drive growth, with new agents and broader imaging use on the horizon - TradingView

Tue, 09 Jun 2026
Lantheus Holdings Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus

Fri, 05 Jun 2026
Assessing Lantheus Holdings (LNTH) Valuation After Strong Multi Month Share Price Gains - Yahoo Finance

Fri, 05 Jun 2026
LNTH News | LANTHEUS HOLDINGS INC (NASDAQ:LNTH) - ChartMill

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	65 (M)
Shares Float	58 (M)
Held by Insiders	2 (%)
Held by Institutions	115.6 (%)
Shares Short	6,440 (K)
Shares Short P.Month	5,110 (K)

EPS	4.19
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	18.62
Profit Margin	18 %
Operating Margin	21.6 %
Return on Assets (ttm)	8.1 %
Return on Equity (ttm)	23.4 %
Qtrly Rev. Growth	1.2 %
Gross Profit (p.s.)	14.36
Sales Per Share	23.8
EBITDA (p.s.)	5.62
Qtrly Earnings Growth	76.5 %
Operating Cash Flow	408 (M)
Levered Free Cash Flow	422 (M)

PE Ratio	24.94
PEG Ratio	0
Price to Book value	5.61
Price to Sales	4.39
Price to Cash Flow	16.69

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.